Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860006 | 0.86 | NR1H4 (0.50) | TRPV1EPHX2NPC1RAB9AIDO1 | |
| SCHEMBL4854757 | 0.83 | ALDH1A1 (0.46) | EPHX2NPC1RAB9AIDO1PLK1 | |
| SCHEMBL4857030 | 0.83 | ALDH1A1 (0.46) | EPHX2NPC1RAB9AIDO1PLK1 | |
| SCHEMBL4853065 | 0.81 | NPC1 (0.47) | EPHX2NPC1RAB9AIDO1PLK1 | |
| SCHEMBL14193769 | 0.81 | NPC1 (0.47) | EPHX2NPC1RAB9AIDO1PLK1 | |
| SCHEMBL4864119 | 0.80 | MEN1 (0.49) | TRPV1NPC1RAB9AIDO1MAPT | |
| SCHEMBL14098636 | 0.80 | EPHX2 (0.73) | TRPV1EPHX2NPC1RAB9AMAPT | |
| SCHEMBL4856115 | 0.80 | MEN1 (0.49) | TRPV1NPC1RAB9AIDO1MAPT | |
| SCHEMBL4860027 | 0.80 | GAA (0.44) | EPHX2NPC1RAB9AIDO1MAPT | |
| SCHEMBL4852963 | 0.80 | IDO1 (0.44) | EPHX2IDO1PLK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1492774-A2 | PYRIMIDONE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATION AND IMMUNOLOGICAL DISEASES | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2005-01-05 | — | — | EP | disclosed |
| US-20040259891-A1 | Novel pyrimidon derivatives | ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) | 2004-12-23 | — | — | US | disclosed |
| US-20030225075-A1 | Novel pyrimidone derivatives | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-12-04 | — | — | US | disclosed |
| WO-2003084938-A2 | PYRIMIDONE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATIN AND IMMUNOLOGICAL DISEASES | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225075-A1 | Novel pyrimidone derivatives | TPMT, TYMP, TYMS | TRPV1 2556/4885EPHX2 3414/4885PTGS1 1288/4885 |
| US-20040259891-A1 | Novel pyrimidon derivatives | TYMS, TPMT, TYMP | TRPV1 1714/4885EPHX2 3006/4885PTGS1 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.